Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Lineage Cell Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Lineage Cell Therapeutics, Inc.

LCTX

Lineage Cell Therapeutics, Inc.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics develops off-the-shelf allogeneic cell therapies targeting neurological and ophthalmic conditions. Its programs include retinal cell replacement for age-related macular degeneration and spinal cord injury repair using pluripotent stem cell-derived cells. The company leverages proprietary differentiation, manufacturing, and delivery technologies, collaborating with partners like Roche. Its focus is on regenerative treatments that restore or support damaged tissues, with a pipeline spanning clinical and preclinical stages.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Lineage Cell Therapeutics, Inc.

1
1
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics Reports 15% Revenue Growth in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics Reports 53% Revenue Growth and Operational Progress in 10-K Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics Reports Q3 2025 Financial Results with $3.68M Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics Reports 96% Revenue Increase in Q2 2025 Amid Rising Losses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics Reports $1.5 Million Revenue in Q1 2025, Net Loss Improves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics Reports 6% Revenue Growth to $9.5 Million in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics Reports 203% Revenue Growth, Improved Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments